Position	Ref_Base	Var_Base	Clinically_Flagged	Valid_Reads	Reference_Reads	Variant_Reads
chr2:215657138	A	G	BARD1  c.247T>C  p.C83R Disrupts RING finger  breast/ovca risk	35	35	0
chr2:215661788	C	T	BARD1 c.212G>A  p.C71Y Disrupts RING finger  breast/ovca risk	177	177	0
chr1:115256528	T	G	NRAS p.Q61H Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	201	200	0
chr1:115256528	T	A	NRAS Q61H Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	201	200	0
chr1:115256529	T	A	NRAS Q61L  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	201	200	0
chr1:115256529	T	C	NRAS Q61R  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	201	200	1
chr1:115256530	G	T	NRAS Q61K Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	202	202	0
chr1:115258744	C	T	NRAS G13D  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	330	330	0
chr1:115258744	C	A	NRAS G13V  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	330	330	0
chr1:115258745	C	G	NRAS G13R  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	332	332	0
chr1:115258747	C	G	NRAS G12A  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	338	338	0
chr1:115258747	C	T	NRAS G12D  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	338	338	0
chr1:115258747	C	A	NRAS G12V  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	338	338	0
chr1:115258748	C	A	NRAS G12C  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	339	339	0
chr1:115258748	C	T	NRAS G12S  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	339	339	0
chr1:162724541	C	A	DDR2 R105S Reported in lung cancer	218	215	2
chr1:162740165	A	G	DDR2 N456S Reported in lung cancer	334	334	0
chr1:162746056	G	T	DDR2 A727S Unknown significance.  Seen once in a non small cell lung cancer at UW	281	281	0
chr1:43815008	T	A	MPL W515K  diagnosis of ET and Primary myelofibrosis when ocurring with G>A chr1:43815009	127	126	1
chr1:43815009	G	A	MPL W515K  diagnosis of ET and Primary myelofibrosis when ocurring with T>A chr1:43815008	127	126	0
chr1:43815009	G	T	MPL W515L  diagnosis of ET and Primary myelofibrosis	127	126	1
chr1:45797228	C	T	MUTYH pathogenic recessive germline variant p.G396D commonly known as p.G382D	83	83	0
chr1:45798115	C	A	MUTYH p.V246F also known as V232F.  Likely pathogenic recessive allele observed in MAP patients and functionally characterized 15673720.	217	212	3
chr1:45798475	T	C	MUTYH p.Y179C pathogenic recessive allele	278	277	0
chr1:97915614	C	T	DPYD IVS14+1 G>A germline.  5-FU CONTRAINDICATED due to toxicity	281	281	0
chr10:123274794	T	C	FGFR2 p.Y376C known hotspot mutation in endometrial cancer	215	212	0
chr10:123279677	G	C	FGFR2 p.S252F activating mutation 17525745	89	89	0
chr11:108199929	T	G	ATM c.7271T>G  p.V2424G Orkney Island allele  well established breast cancer risk  9463314 and unpublished data	113	113	0
chr12:12022722-12022731	TCTGATCCTG	-	ETV6 del seen once at UW	229	227	0
chr12:133244199	T	C	POLE T737A Alaskan native allele	285	285	0
chr12:133250250	C	G	POLE p.L424V pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	175	175	0
chr12:133250250	G	C	POLE p.L424V pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	175	175	0
chr12:25378562	C	T	KRAS A146T probable resistance to EGFR inhibitors in colon cancer	179	179	0
chr12:25378647	T	A	KRAS K117N probable resistance to EGFR inhibitors in colon cancer	197	197	0
chr12:25378647	T	G	KRAS K117N probable resistance to EGFR inhibitors in colon cancer	197	197	0
chr12:25380275	T	G	KRAS Q61H Probable resistance to EGFR inhibitors in colon cancer	168	168	0
chr12:25380275	T	A	KRAS Q61H Probable resistance to EGFR inhibitors in colon cancer	168	168	0
chr12:25380276	T	A	KRAS Q61L Probable resistance to EGFR inhibitors in colon cancer	167	167	0
chr12:25380276	T	G	KRAS Q61P Probable resistance to EGFR inhibitors in colon cancer	167	167	0
chr12:25380276	T	C	KRAS Q61R Probable resistance to EGFR inhibitors in colon cancer	167	167	0
chr12:25380277	G	T	KRAS Q61K Probable resistance to EGFR inhibitors in colon cancer	164	164	0
chr12:25380283	C	T	KRAS A59T unknown response to EGFR inhibtiors but reported in colorectal cancer 20619739	165	164	1
chr12:25398281	C	T	KRAS G13D  possible resistance to EGFR inhibitors. See literature.	147	144	0
chr12:25398281	C	A	KRAS G13V  resistance to EGFR inhibitors in colon cancer	147	144	2
chr12:25398282	C	A	KRAS G13C  resistance to EGFR inhibitors in colon cancer	142	142	0
chr12:25398282	C	T	KRAS G13S  resistance to EGFR inhibitors in colon cancer	142	142	0
chr12:25398284	C	G	KRAS G12A  resistance to EGFR inhibitors in colon cancer	143	143	0
chr12:25398284	C	T	KRAS G12D  resistance to EGFR inhibitors in colon cancer	143	143	0
chr12:25398284	C	A	KRAS G12V  resistance to EGFR inhibitors in colon cancer	143	143	0
chr12:25398285	C	A	KRAS G12C  resistance to EGFR inhibitors in colon cancer	145	145	0
chr12:25398285	C	G	KRAS G12R  resistance to EGFR inhibitors in colon cancer	145	145	0
chr12:25398285	C	T	KRAS G12S  resistance to EGFR inhibitors in colon cancer	145	145	0
chr13:28592641	T	A	FLT3 D835V  TKD mutation	309	307	0
chr13:28592642	C	G	FLT3 D835H  TKD mutation	306	304	0
chr13:28592642	C	T	FLT3 D835N  TKD mutation	306	304	2
chr13:28592642	C	A	FLT3 D835Y  TKD mutation	306	304	0
chr13:32900625	T	C	Germline Previously reported as VUS by Myriad IVS6-11T>C	146	146	0
chr13:32914438	T	-	BRCA2 6174delT AJ founder mutation	236	234	0
chr13:32919384	T	G	BRCA2 IVS12 7164 (+594) c.6937(+594) T>G mRNA ins [IVS12(+495 to +589)] (Silvia)	0	0	0
chr13:32936674	C	T	BRCA2 c.7820 C>T  p.T2607I mRNA skip ex17 and ex17-18 (Silvia)	103	103	0
chr13:32936733	A	T	BRCA2 c.7879 A>T  p.I2627F mRNA skip ex 17-18 (Silvia)	153	153	0
chr13:32937327	A	T	BRCA2 c.7988 A>T  p.E2663V mRNA skip ex 18 (Silvia)	119	117	1
chr13:32937348	C	T	BRCA2 c.8009 C>T  p.S2670L mRNA skip ex 18 (Silvia)	135	135	0
chr13:32937506	G	C	BRCA2 C.8167  p.D2723H Disrupts nuclear export signal  24013206	278	278	0
chr13:32937506	G	C	BRCA2 p.D2723H pathogenic PMID 24013206 and 15290653	278	278	0
chr13:32937507	A	G	BRCA2 c.8168 A>G  p.D2723G mRNA 8396 del 164 (Silvia)	277	276	1
chr14:105246551	C	T	AKT1 p.E17K is a recurrent activating mutation in many cancers.  It may be targetable by AKT inhibitors	144	143	1
chr15:43762078-43762083	GGGATA	-	TP53BP1 c.1347_1352del benign nonframeshift ins	0	0	0
chr15:66727455	G	T	MEK1 K57N Constituitive activation. In vitro response to MEK inhibitor AZD6244 and in vitro resistance to TKIs.	217	217	0
chr15:90631934	C	T	IDH2 R140Q  prognosis in AML	144	142	0
chr15:90631935	G	A	IDH2 p.R140W PROGNOSIS in AML	139	138	0
chr16:2124321	C	A	TSC2 L826M Germline probably benign. Annotated as rare polymorphism in TSC project db	74	74	0
chr16:68845646	G	A	CDH1 p.A298T germline VUS vs likely deleterious.  Reported in one family with diffuse gastric cancer and shown to be damaging to E-cadherin in an in vitro assay 15235021.	241	240	0
chr16:68862107	G	A	CDH1  c.2195G>A  p. R732Q Lobular breast cancer risk 17545690	310	310	0
chr17:37880981	-	GCATACGTGATG	ERBB2 (HER2) exon 20 insertion probably senstizies to dual EGFR HER2 TKIs in NSCLC	149	148	0
chr17:37881000	G	T	The p.V777L mutation lies within the kinase domain and has been reported in gastric colorectal and breast cancers (Lee 2006). Recent preclinical work has demonstrated that breast cancer cell lines harboring the p.V777L mutation were sensitive to trastuzumab lapatinib and neratinib (Bose 2013).	165	165	0
chr17:37881002	-	GGCTCCCCA	ERBB2 (HER2) exon 20 insertion probably senstizies to dual EGFR HER2 TKIs in NSCLC	170	170	0
chr17:41203121	A	G	BRCA1 c.5291 T>C  p.L1764P Definitely pathogenic per IARC	117	117	0
chr17:41209079	-	G	BRCA1 5382insC AJ founder mutation	242	241	0
chr17:41209139	A	C	BRCA1 c.5207 T>G  p.V1736G mRNA skip ex 20  reduced mutant message (Silvia)	234	234	0
chr17:41219627	G	A	BRCA1 c.5072 C>T  p.T1691I mRNA skip ex 17 (Silvia)	157	155	0
chr17:41234558	A	G	BRCA1 c.4220 T>C  p.L1407P Disrupts coiled-coil structure	125	123	1
chr17:41243509	T	C	BRCA1 161x in BIC probably not important	224	222	1
chr17:41267746	C	A	BRCA1 c.131 G>T  p.C44F Loss of ubiquitin ligase activity	135	134	1
chr17:41276045-41276046	CT	-	BRCA1 185delAG AJ founder mutation	96	96	0
chr17:46805705	C	T	HOXB13 G84E prostate cancer risk allele 23518396 23064873	1	1	0
chr17:56774077	A	G	RAD51C  c.428A>G  p.Q143R. Ovca risk (Swisher) and 22451500	173	172	1
chr17:7578406	C	T	TP53 R175H well described deleterious germline and somatic mutation	139	139	0
chr19:3118942	A	T	GNA11 Q209L activating mutation in 34% of uveal melanomas.  Usually exclusive of other drivers such as BRAF KIT and NRAS	131	130	0
chr19:33792731	-	GCGGGT	CEBPA known benign germline polymorphism in TAD2 domain PMID: 17851556 	0	0	0
chr19:45854919	T	G	ERCC2 rs13181T>G.  G allele worse response to oxaliplatin therapy in colorectal cancer 21278243 	178	106	72
chr19:45923653	A	G	ERCC1 rs11615T>C.  T allele worse response to oxaliplatin therapy in colorectal cancer 21278243 	1	1	0
chr19:50909713	G	A	POLD1 p.S478N pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	113	112	0
chr19:50909713	C	T	POLD1 p.S478N pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	113	112	1
chr2:209113112	C	T	IDH1 R132H  glioma diagnosis  prognosis in AML	194	193	0
chr2:209113112	C	A	IDH1 R132L  glioma diagnosis  prognosis in AML	194	193	1
chr2:209113113	G	A	IDH1 R132C  glioma diagnosis  prognosis in AML	194	194	0
chr2:209113113	G	C	IDH1 R132G  glioma diagnosis  prognosis in AML	194	194	0
chr2:215661841	A	C	BARD1  c.159T>G  p.C53W Disrupts RING finger  breast/ovca risk	189	189	0
chr2:25457191	C	T	DNMT3A R899H  unclear significance  look up	253	253	0
chr2:25457242	C	T	DNMT3A R882H  prognosis and treatment in AML	227	227	0
chr2:25457243	G	A	DNMT3A R882C  prognosis and treatment in AML	223	222	1
chr2:25457243	G	T	DNMT3A R882S  prognosis and treatment in AML	223	222	0
chr2:25463541	G	C	DNMT3A S714C  unclear significance but seen in multiple AML patients  look up	180	180	0
chr2:25467437	G	A	DNMT3A L547F  unclear significance  look up	188	187	0
chr2:25467449	C	A	DNMT3A G543C  probably relevant for AML	207	205	1
chr2:47641560	A	T	MSH2 c.942+3 A>T pathogenic Lynch mutation within noisy microsatellite tract.  Can be missed by variant callers.	50	32	0
chr2:47693788	A	T	MSH2 NM_000251:exon10:c.1511-9A>T Reported 26 times in InSight and benign	214	212	0
chr2:48026168	A	G	MSH6 Q349R Germline VUS	496	495	0
chr2:48027269-48027272	CAGT	-	MSH6 deletion seen twice TIDB1232	364	363	0
chr2:48027755	T	C	MSH6 V878A 41 hits in Insight with conflicting literature (we have reported as VUS)	358	355	1
chr2:48030646	C	G	MSH6 P1087R Germline probably benign PMID 12019211	385	383	1
chr20:31022441	-	G	ASXL1 Frameshift seen in OPX-0003T	104	100	1
chr20:57484420	C	T	GNAS p.R201C is an activating mutation in fibrous dsyplasia and other neoplasms.  May be germline or somatic.  Germline associated McCune-Albright syndrome	301	301	0
chr20:57484421	G	A	GNAS p.R201H is an activating mutation in fibrous dsyplasia and other neoplasms.  May be germline or somatic.  Germline associated McCune-Albright syndrome	301	300	0
chr22:29091207	G	A	CHEK2  p.S428F	182	182	0
chr22:29091857	G	-	CHEK2 1100delC~2-3 fold increased breast cancer risk	141	141	0
chr22:29121058	C	T	CHEK2  p.G167R	246	245	0
chr22:29121077	T	C	CHEK2  p.I160M	245	244	1
chr22:29121087	A	G	CHEK2 I157T 1.5 fold increase in breast cancer risk 1.7 fold increase in colon cancer risk	246	246	0
chr22:29121242	G	A	CHEK2  p.R145W 	275	273	0
chr22:29121247	T	C	CHEK2  p.H143R	274	270	1
chr22:29130450-29130464	TCCTCAGGTTCTTGG	-	CHEK2 benign in frame deletion	169	168	0
chr22:29130520	C	T	"CHEK2 p.E64K VUS.   This variant has been reported before at least once and was shown to partially reduce CHEK2 protein kinase activity (Wu 2006).  In a different functional assay system (Roeb 2012) the CHEK2 p.E64K variant was also shown to impact CHEK2 protein function (Mary Claire King, personal communication).  "	154	153	0
chr3:178921553	T	A	PIK3CA p.N345K a known activating mutation	98	98	0
chr3:178927980	T	C	PIK3CA (p.C420R) - Activating mutation demonstrated in vitro (PMID 15647370)	107	106	1
chr3:178936082	G	A	PIK3CA E542K recurrent mutation.  Possible increased response to PI3K inhibitors	99	98	0
chr3:178936091	G	A	PIK3CA E545K Activating mutation found in diverse cancers.  Seen in GB-2T lung cancer	102	102	0
chr3:178938934	G	A	PIK3CA p.E726K recurrent hotspot	113	113	0
chr3:178952084	C	T	PIK3CA H1047Y is an activating mutation	172	172	0
chr3:178952085	A	T	PIK3CA H1047L Activating PIK3CA mutation.	170	169	0
chr3:178952085	A	G	PIK3CA H1047R Very common activating PIK3CA mutation.  Pre-clinical data suggests response to PI3K inhibitors	170	169	0
chr3:37034946	G	A	MLH1 c.-93G>A promoter polymporphism is associated with sporadic MLH1 loss and MSI-H but not with increased cancer risk	445	231	213
chr3:37038192	G	A	MLH1 p.G67R - known pathogenic mutation observed in LMG1169 (TIDB 1952) and LMG-1836 (TIDB 2342)	425	424	0
chr3:37067306	G	A	MLH1 S406N Germline LIKELY BENIGN Class II variant	367	367	0
chr3:41266113	C	T	CTNNB1 p.S37F Common activating Beta catenin mutation	249	249	0
chr3:41266113	C	A	CTNNB1 p.S37Y Common activating Beta catenin mutation	249	249	0
chr3:41266137	C	T	CTNNB1 p.S45F Common activating Beta catenin mutation	239	239	0
chr3:41266137	C	A	CTNNB1 p.S45Y Common activating Beta catenin mutation	239	239	0
chr3:52442072	T	C	T93A new splice acceptor in RCC and breast cancer 23684012	97	96	1
chr3:52442072	T	C	BAP1 T93A renal cell carcinoma risk	97	96	1
chr4:55152093	A	T	PDGFRA D842V treatment responses in GIST	267	265	0
chr4:55593589-55593609	TGTATGAAGTACAGTGGAAGG	-	KIT 21bp exon 11 del response to imitanib in GIST	270	270	0
chr4:55593590-55593607	GTATGAAGTACAGTGGAA	-	KIT p.552_558del exon 11 imatinib sensitivity in GIST	269	268	0
chr4:55593601-55593615	AGTGGAAGGTTGTTG	-	KIT p.556_561del exon 11 imatinib sensitivity in GIST	264	263	0
chr4:55594221	A	G	K642E  predicts sensitivity to imatinib in melanoma	253	253	0
chr4:55599340	T	A	KIT p.N822K Recurrent Exon 17 Mutation in AML	195	194	0
chr4:55955969	C	T	KDR p.A1065T probably activating mutation.  In vitro evidence of response to VEGFR inhibitors PMID 19723655	242	241	0
chr4:84383770	C	T	 FAM175A/ABRAXAS c.1082G>A  p.R361Q Damaging to NLS  breast cancer risk 22357538	306	306	0
chr5:112115546	G	A	APC:c.532-941G>A GERMLINE probably pathogenic splice 22431159 	0	0	0
chr5:112158419	C	T	APC:c.1408+731C>T GERMLINE probably pathogenic splice 22431159 	0	0	0
chr5:112158423	A	T	APC:c.1408+735A>T GERMLINE probably pathogenic splice 22431159 	0	0	0
chr5:112173250	G	A	APC c.1959 G to A is probably a benign silent germline variant Aretz et al 15459959	125	124	0
chr5:112175211	T	A	APC I1307K Jewish APC allele pathogenic germline low penetrance colon cancer risk 11001924	261	261	0
chr5:170837543	-	TCTG	NPM1 c.772_773insTCTG  prognosis in AML	66	66	0
chr5:170837544	-	CTGC	NPM1c.773_774insCTGC  prognosis in AML	68	68	0
chr5:170837545	-	TGCA	NPM1 c.861_862insTGCA good prognosis in AML	69	69	0
chr5:67591118-67591135	ATCCAGCTGAGAAAGACG	-	PIK3R1 in frame deletion first seen by us in KA2T breast cancer.	207	207	0
chr7:140453134	T	C	BRAF K601E is probably an activating mutation	167	167	0
chr7:140453135	C	T	BRAF V600E variant probable  check position chr7:140453136	163	163	0
chr7:140453136	A	T	BRAF V600E common T>A sensitizes to BRAF inhibitors	164	164	0
chr7:140453137	C	T	BRAF V600K probable  check position chr7:140453136	166	166	0
chr7:140481393	A	C	BRAF A472S reported once in endometrial ca unclear significance 16144912	333	332	1
chr7:140481402	C	A	BRAF G469V highly conserved GXGXXG motif of the kinase domain. G469A in my cancer genome 	344	343	0
chr7:55241677	G	A	EGFR E709K probably sensitizes to TKIs	227	227	0
chr7:55241678	A	C	EGFR E709A probably sensitizes to TKIs	224	222	0
chr7:55241678	A	T	EGFR E709V probably sensitizes to TKIs	224	222	0
chr7:55241707	G	T	EGFR G719C probably sensitizes to TKIs	200	200	0
chr7:55241707	G	A	EGFR G719S probably sensitizes to TKIs	200	200	0
chr7:55241708	G	C	EGFR G719A probably sensitizes to TKIs	202	200	0
chr7:55242465-55242479	GGAATTAAGAGAAGC	-	EGFR exon 19 p.745_750del sensitizes to TKIs	243	242	0
chr7:55242466-55242480	GAATTAAGAGAAGCA	-	EGFR p.746_750del (exon 19 del) Sensitizes to TKIs (seen in GB-6T)	241	241	0
chr7:55242470-55242487	TAAGAGAAGCAACATCTC	-	EGFR p.747_753del sensitizes to TKIs	243	242	0
chr7:55248998	-	TGGCCAGCG	EGFR exon 20 insertion Lack of Response to TKIs (seen in OPX-0002T)	95	95	0
chr7:55249005	G	T	EGFR p.S768I probably sensitizes to TKIs	98	98	0
chr7:55249071	C	T	EGFR T790M resistance to TKIs	153	153	0
chr7:55259515	T	G	EGFR L858R sensitizes to TKIs	188	188	0
chr7:55259524	T	A	EGFR L861Q probably sensitizes to TKIs	186	185	0
chr7:6045549	C	A	PMS2 p.S46I known pathogenic germline variant	174	174	0
chr8:90983442-90983446	TTTGT	-	Slavic founder allele >2 fold risk for breast cancer.  Correct HGVS: NM_002485.4:c.657_661del p.(Lys219Asnfs*16)	70	70	0
chr8:90983460	G	A	NBN p.R215W germline.  This variant should go on a report because some groups report as pathogenic and associated with increased breast cancer risk.  We feel it is likely benign based on similar frequency in cases and controls. 	62	62	0
chr9:101594229	G	A	GALNT12 p.D303N Germline Colon Cancer Risk Allele	0	0	0
chr9:133738363	G	A	ABL1 E255K Imatinib resistance in CML	146	146	0
chr9:133748288	T	A	ABL1 F317I dasatinib resistance in cell culture models	104	104	0
chr9:133748288	T	C	ABL1 F317L imatinib- and dasatinib-resistance in CML	104	104	0
chr9:133750356	A	C	ABL1 H396P imatinib- and dasatinib-resistance in CML	206	205	0
chr9:5073770	G	T	V617F  myeloproliferative disorder diagnosis JAK2 inhibitor responsiveness	163	162	1
chr9:80409488	A	T	GNAQ Q209L Uveal melanoma hotspot 	133	133	0
chr9:80409488	A	C	GNAQ Q209P Uveal melanoma hotspot 	133	133	0
chr9:80409488	T	G	GNAQ Q209P Uveal melanoma hotspot 	133	133	0
